Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enoxaparin in 1st-line advanced NSCLC
NCT01058759Phase 3Terminated
- Sponsor
- Hannover Medical School
- Start
- Nov 2009
- Primary completion
- Feb 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of enoxaparin in non-small cell lung cancer (NSCLC), sponsored by Hannover Medical School. Started Nov 2009; status: terminated.
02
Drugs
enoxaparin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01058759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01058759.